06Oct 2023
Novel lipid metabolomic signature detects atherosclerosis progression in young people with juvenile‐onset SLE

Novel lipid metabolomic signature detects atherosclerosis progression in young people with juvenile‐onset SLE

The APPLE trial, focusing on juvenile-onset systemic lupus erythematosus (JSLE), reveals distinct atherosclerosis progression patterns despite low cardiovascular risk. Unsupervised clustering identified high, intermediate, and low CIMT trajectories. A metabolomic signature predicts high CIMT progression in the placebo group. Atorvastatin reduced LDL, but 36% still had high progression, not predicted by metabolomic biomarkers, highlighting non-lipid factors.

  • #rheumatology

Like

Save

Share